Technology ID
TAB-3738
Method For Improving Insulin Sensitivity for the Treatment of Diabetes
E-Numbers
E-081-2019-0
Lead Inventor
Nieman, Lynnette (NICHD)
Co-Inventors
Ulmann, Andre (CEMAG CARE)
Newman, Arnold (Unit Cell Diamond)
Applications
Therapeutics
Therapeutic Areas
Endocrinology
Lead IC
NIDDK
ICs
NICHD
This technology includes the administration of the antiglucocorticoid mifepristone for the treatment of diabetes. Administration of mifepristone (50 mg orally every 6 hours) for one week improves hepatic and adipose insulin resistance in men and women with pre-diabetes or mild type 2 diabetes mellitus.
Commercial Applications
Treatment of insulin resistance, type 2 diabetes.
Competitive Advantages
This class of compounds has not been previously used for the treatment of insulin resistance, which is found in patients with prediabetes and diabetes type 2. Thus, it is a novel discovery that may have important therapeutic applications in the many patients with these disorders.
Licensing Contact: